Pinned Tweet
1/ Unpopular take: in vivo CAR-T will get sandwiched between ex vivo CARs and biologics (TCEs, ADCs). I think its only durable advantage is cost, and that's solvable. 🧵
1
1
184
Armon Sharei, PhD retweeted
We’ve been quiet here, but our cells haven’t!
We’re back on X with a hypothesis: Galaxy-i deserves a 2027 Scientists’ Choice Award. 🏆
Help us prove it: selectscience.jotform.com/26…
5/ The experiment: we used Portal’s research-scale system (the Gateway) to deliver all the sequences to primary human PBMCs (T, B, NK cells and monocytes) and did the readout on D3.
1
1
13
6/ Don’t forget, always say ‘please’ in case they take over the world 😉
Reply: Full post on LinkedIn: linkedin.com/feed/update/urn…
1
9
Armon Sharei, PhD retweeted
Incredible data from Armon Sharei at @portal_biotech this week.
@AnthropicAI's Claude designed siRNA that knocked down two different genes. @OpenAI's GPT-5 and @GoogleDeepMind's Gemini designed sequences that did nothing.
Armon used the same one line prompt across all three models: "Please give me your top 3 siRNA sequences for knocking down [gene] in human peripheral blood mononuclear cells."
siRNA is small interfering RNA. A short piece of RNA that finds the matching mRNA inside a cell and destroys it. The gene stays intact, the message never becomes a protein. The hard part is picking a sequence that hits the right transcript and nothing else.
The two targets were B2M and CD45. Both well known, both already carrying real clinical programs.
B2M, beta-2 microglobulin. The shared subunit of every MHC class I molecule.
- @CRISPRTX zugocaptagene geleucel, formerly CTX112. CD19 allogeneic CAR T, B2M knocked out for immune evasion
- @SanaBiotech SC291. CD19 allogeneic CAR T on their hypoimmune platform: B2M and CIITA out, CD47 in
CD45, also called PTPRC. The pan-leukocyte phosphatase, on every white blood cell and almost nothing else.
- @ActiniumPharma Iomab-B, an iodine-131 anti-CD45 antibody, Phase 3 in AML
One is a target for making allogeneic T cells. The other is a target for clearing a patient's own blood cells out of the marrow so that a donor stem cell graft has room to engraft.
The results, with all sequences delivered straight into the cytosol of primary human PBMCs on Portal's Gateway and read out at day 3:
B2M, non-targeting control 7.5%
- Claude: 74.7%
- GPT-5: 26.8%
- Gemini: 5.5%
CD45, non-targeting control 0.7%
- Claude: 97.9%
- GPT-5: 2.8%
- Gemini: 5.6%
The type of design thinking necessary to come up with an siRNA construct used to take specialized skills and know-how.
Today, in one prompt, we have access to 0-shot siRNA design.
6/ So today the edge is cost: one injection vs. centralized GMP manufacturing. But if a machine makes the cells at the point of care, that edge disappears and controllability wins. Full write-up in the reply 👇
1
41
Full write-up on LinkedIn: linkedin.com/feed/update/urn…
18
Armon Sharei, PhD retweeted
💸 What do investment bankers actually do?
🎙️Listen to Episode 9 of Boba & Biotech with Armon Sharei featuring guest Mark Dempster on all streaming platforms today!
🎤Available on all streaming platforms!
open.spotify.com/episode/5wX…
—
#biotech #IB #investmentbanking #startups
Armon Sharei, PhD retweeted
☠️It was part of his job to kill programs?
🎙️Listen to Episode 8 of Boba & Biotech with Armon Sharei featuring guest William Pao on all streaming platforms today!
🎤Available on all streaming platforms!
open.spotify.com/episode/1kU…
—
#science #biotech #boba #startups
Armon Sharei, PhD retweeted
🧗AI’s biggest cliff…
🎙️Listen to Episode 8 of Boba & Biotech with Armon Sharei featuring guest William Pao on all streaming platforms today!
open.spotify.com/episode/1kU…
—
#science #biotech #spotifypodcasts #boba #startups
Armon Sharei, PhD retweeted
📈Why most biotech startups fail…
🎙️Listen to Episode 6 of Boba & Biotech with Armon Sharei featuring guest Adam Jenkins on all streaming platforms today!
open.spotify.com/episode/32u…
—
#science #biotech #spotifypodcasts #boba #startups
Armon Sharei, PhD retweeted
🚀The risks startups take to launch
🎙️Listen to Episode 5 of Boba & Biotech with Armon Sharei featuring guest Klavs Jensen on all streaming platforms today!
open.spotify.com/episode/167…
#science #biotech #spotifypodcasts #boba #startups





